Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

MYC inhibitors in multiple myeloma

  • Martínez-Martín, Sandra|||0000-0003-4443-0697
  • Soucek, Laura|||0000-0002-4750-7971
The importance of MYC function in cancer was discovered in the late 1970s when the sequence of the avian retrovirus that causes myelocytic leukemia was identified. Since then, over 40 years of unceasing research have highlighted the significance of this protein in malignant transformation, especially in hematologic diseases. Indeed, some of the earliest connections among the higher expression of proto-oncogenes (such as MYC), genetic rearrangements and their relation to cancer development were made in Burkitt lymphoma, chronic myeloid leukemia and mouse plasmacytomas. Multiple myeloma (MM), in particular, is a plasma cell malignancy strictly associated with MYC deregulation, suggesting that therapeutic strategies against it would be beneficial in treating this disease. However, targeting MYC was - and, somehow, still is - challenging due to its unique properties: lack of defined three-dimensional structure, nuclear localization and absence of a targetable enzymatic pocket. Despite these difficulties, however, many studies have shown the potential therapeutic impact of direct or indirect MYC inhibition. Different molecules have been tested, in fact, in the context of MM. In this review, we summarize the current status of the different compounds, including the results of their clinical testing, and propose to continue with the efforts to identify, repurpose, redesign or improve drug candidates to combine them with standard of care therapies to overcome resistance and enable better management of myeloma treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting MYC-driven lymphoma, lessons learned and future directions

  • Martínez-Martín, Sandra|||0000-0003-4443-0697
  • Beaulieu, Marie-Eve|||0000-0001-5224-8436
  • Soucek, Laura|||0000-0002-4750-7971
MYC plays a central role in tumorigenesis by orchestrating cell proliferation, growth and survival, among other transformation mechanisms. In particular, MYC has often been associated with lymphomagenesis. In fact, MYC overexpressing lymphomas such as high-grade B-cell lymphoma (HGBL) and double expressor diffuse large B-cell lymphomas (DLBCL), are considered addicted to MYC. In such a context, MYC targeting therapies are of special interest, as MYC withdrawal is expected to result in tumor regression. However, whether high MYC levels are always predictive of increased sensitivity to these approaches is not clear yet. Even though no MYC inhibitor has received regulatory approval to date, substantial efforts have been made to investigate avenues to render MYC a druggable target. Here, we summarize the different classes of molecules currently under development, which mostly target MYC indirectly in aggressive B-cell lymphomas, paying special attention to subtypes with MYC/BCL2 or BCL6 translocations or overexpression.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer

  • Giuntini, Fabio
  • González-Larreategui, Íñigo|||0000-0002-0959-8497
  • Herencia-Ropero, Andrea|||0009-0002-9448-1484
  • Casacuberta-Serra, Sílvia|||0000-0002-2595-1115
  • Zacarías-Fluck, Mariano F.|||0000-0002-7171-4268
  • Arnal, Magdalena|||0000-0001-8647-9232
  • Pedretti, Flaminia
  • Martínez-Martín, Sandra|||0000-0003-4443-0697
  • Thabussot, Hugo
  • Cano, Virginia Castillo
  • Grueso, Judit|||0000-0003-1093-7940
  • Foradada Felip, Laia|||0000-0002-0589-4360
  • Serrano, Erika
  • López-Estévez, Sergio|||0000-0001-5355-8073
  • Rodriguez, Olga
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodriguez-Hernandez, Adela
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Nonell, Lara|||0000-0002-8538-8213
  • Prat, Aleix|||0000-0003-2377-540X
  • Serra, Violeta|||0000-0001-6620-1065
  • Beaulieu, Marie-Eve|||0000-0001-5224-8436
  • Whitfield, Jonathan R.|||0000-0002-4925-7283
  • Massó Vallés, Daniel|||0000-0003-4231-0456
  • Soucek, Laura|||0000-0002-4750-7971
MYC is dysregulated in most human cancers and is a DNA damage response (DDR) modulator capable of both promoting genomic instability and enhancing DNA repair. Here, we show that Omomyc, the only direct MYC inhibitor that has completed a phase 1 trial, shuts down DDR genes in triple-negative breast cancer (TNBC), causing DDR defects and inducing DNA damage. Since DDR-deficient tumors are currently targeted by poly ADP-ribose polymerase inhibitors (PARPis), we tested combinations with Omomyc. We show that Omomyc-induced DNA damage is enhanced by PARPis and that the inhibitors cooperate even in models with intrinsic or acquired PARPi resistance, both in vitro and in vivo. Moreover, using patient-derived models and clinical samples, we reveal a role for MYC as a predictor of PARPi resistance. Overall, our research highlights the opportunity of combining MYC inhibition by Omomyc with PARPis in PARPi-resistant TNBC, where MYC transcriptional activity represents a predictive biomarker of resistance to therapy.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition

  • Giuntini, Fabio
  • Massó-Vallés, Daniel
  • Whitfield, Jonathan
  • Soucek, Laura
DNA damage response; DNA damage response inhibitors; MYC inhibition, Respuesta al daño del ADN; Inhibidores de la respuesta al daño del ADN; Inhibición de MYC, Resposta al dany de l'ADN; Inhibidors de la resposta al dany de l'ADN; Inhibició de MYC, MYC performs a dual role in DNA Damage Response (DDR), promoting genomic instability through replication stress, R-loop formation, and topoisomerase-mediated damage, while simultaneously activating DNA repair pathways to maintain cell survival. This review provides a comprehensive analysis of how MYC inhibition affects DDR pathway dependencies. In fact, when MYC is inhibited, cancer cells lose both their proficient DNA repair capacity and their protective mechanisms against replication stress. This creates a therapeutic window in which combining MYC inhibitors with DDR-targeting agents may achieve synergistic anti-cancer effects. Central to this approach is the exploration of rational combination strategies that pair MYC inhibitors with various DDR modulators including Poly (ADP-ribose) polymerase (PARP) inhibitors, ATR/CHK1 inhibitors, and other DNA repair pathway disruptors. This review summarizes preclinical evidence demonstrating enhanced therapeutic efficacy when MYC inhibition is combined with DDR-targeting agents and discusses early clinical findings that support this promising therapeutic strategy., The author(s) declared that financial support was received for this work and/or its publication. We thank the Spanish Association of Metastatic Breast Cancer for the Chiara Giorgetti Award 2022, Instituto de Salud Carlos III (FI20/00274 – FG PFIS doctoral bursary), Ministerio de Ciencia e Innovación (Retos de Colaboración RTC2019-007067-1, Líneas Estratégicas PLEC2021-007959), Generalitat de Catalunya (AGAUR 2017/SGR 537 and 2021/SGR 01509), EDIReX (H2020 INFRAIA 731105-2), the European Research Council (ERC-2023-ADG 101142260), the Spanish Ministry of Science and Innovation and European Union through the NextGenerationEU program, in the context of the Plan de Recuperacion, Transformacion y Resiliencia (RETOS; CPP2022-009808) and the FERO foundation for funding support.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer

  • Giuntini, Fabio
  • Zacarias Fluck, Mariano F
  • Arnal, Magdalena
  • Pedretti, Flaminia
  • Grueso, Judit
  • Guzman Torres, Marta
  • González-Larreategui, Íñigo
  • Herencia Ropero, Andrea
  • Casacuberta-Serra, Sílvia
  • Serrano del Pozo, Erika
  • Rodríguez, Olga
  • Llop-Guevara, Alba
  • Balmaña, Judith
  • Nonell, Lara
  • Whitfield, Jonathan
  • Soucek, Laura
  • Serra, Violeta
Cancer; DNA damage; Omomyc, Càncer; Dany a l'ADN; Omomyc, Cáncer; Daño en el ADN; Omomyc, MYC is dysregulated in most human cancers and is a DNA damage response (DDR) modulator capable of both promoting genomic instability and enhancing DNA repair. Here, we show that Omomyc, the only direct MYC inhibitor that has completed a phase 1 trial, shuts down DDR genes in triple-negative breast cancer (TNBC), causing DDR defects and inducing DNA damage. Since DDR-deficient tumors are currently targeted by poly ADP-ribose polymerase inhibitors (PARPis), we tested combinations with Omomyc. We show that Omomyc-induced DNA damage is enhanced by PARPis and that the inhibitors cooperate even in models with intrinsic or acquired PARPi resistance, both in vitro and in vivo. Moreover, using patient-derived models and clinical samples, we reveal a role for MYC as a predictor of PARPi resistance. Overall, our research highlights the opportunity of combining MYC inhibition by Omomyc with PARPis in PARPi-resistant TNBC, where MYC transcriptional activity represents a predictive biomarker of resistance to therapy., We acknowledge the kind support from the Vall d’Hebron Institute of Oncology and the Cellex Foundation for providing research facilities and equipment. We thank the Spanish Association of Metastatic Breast Cancer for the Chiara Giorgetti Award 2022, Instituto de Salud Carlos III (FI20/00274 – F.G., PFIS doctoral bursary); Ministerio de Ciencia e Innovación (Retos de Colaboración RTC2019-007067-1 and Líneas Estratégicas PLEC2021-007959); Generalitat de Catalunya (AGAUR 2017/SGR 537 and 2021/SGR 01509); EDIReX (H2020 INFRAIA 731105-2); the European Research Council (ERC-2023-ADG 101142260); the Spanish Ministry of Science and Innovation and the European Union through the NextGenerationEU program, in the context of the Plan de Recuperacion, Transformacion y Resiliencia (RETOS; CPP2022-009808); and the Fero Foundation for funding support.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue

  • Martínez Martín, Sandra
  • Castillo Cano, Virginia
  • Massó Vallés, Daniel
  • López-Estévez, Sergio
  • Thabussot, Hugo
  • Beaulieu, Marie-Eve
  • Soucek, Laura
  • Foradada Felip, Laia
  • Kaur, Jastrinjan
  • Serrano del Pozo, Erika
Omomyc; Mass spectrometry; Protein therapeutics, Omomyc; Espectrometría de masas; Terapéutica de proteínas, Omomyc; Espectrometria de masses; Terapèutica de proteïnes, MYC is an oncoprotein causally involved in the majority of human cancers and a most wanted target for cancer treatment. Omomyc is the best-characterized MYC dominant negative to date. In the last years, it has been developed into a therapeutic miniprotein for solid tumor treatment and recently reached clinical stage. However, since the in vivo stability of therapeutic proteins, especially within the tumor vicinity, can be affected by proteolytic degradation, the perception of Omomyc as a valid therapeutic agent has been often questioned. In this study, we used a mass spectrometry approach to evaluate the stability of Omomyc in tumor biopsies from murine xenografts following its intravenous administration. Our data strongly support that the integrity of the functional domains of Omomyc (DNA binding and dimerization region) remains preserved in the tumor tissue for at least 72 hours following administration and that the protein shows superior pharmacokinetics in the tumor compartment compared with blood serum., This research has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 872212 and from the Ministerio de Ciencia e Innovacion under grant no. RTC2019-007067-1.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma

  • Zacarias Fluck, Mariano F
  • Massó-Vallés, Daniel
  • Giuntini, Fabio
  • González-Larreategui, Íñigo
  • Kaur, Jastrinjan
  • Casacuberta-Serra, Sílvia
  • Jauset González, Antoni
  • Martínez Martín, Sandra
  • Martín Fernández, Génesis
  • Serrano del Pozo, Erika
  • Foradada Felip, Laia
  • Grueso Gragera, Judit
  • Nonell Malezon, Lara
  • Whitfield, Jonathan
  • Beaulieu, Marie-Eve
  • Soucek, Laura
MYC; Omomyc; Melanoma, MYC; Omomyc; Melanoma, MYC; Omomyc; Melanoma, MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway—the most predominantly mutated pathway in this disease—turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. Here, by making use of Omomyc, the most characterized MYC inhibitor to date that has just successfully completed a phase I clinical trial, we show for the first time that MYC inhibition in melanoma induces remarkable transcriptional modulation, resulting in severely compromised tumor growth and a clear abrogation of metastatic capacity independently of the driver mutation. By reducing MYC's transcriptional footprint in melanoma, Omomyc elicits gene expression profiles remarkably similar to those of patients with good prognosis, underlining the therapeutic potential that such an approach could eventually have in the clinic in this dismal disease., M.F.Z.-F. was supported by the Juan de la Cierva Programme of the Spanish Ministry of Economy and Competitiveness (IJCI-2014-22403) and Fundació La Marató de TV3 (grant 474/C/2019); F.G. was supported by Spanish Ministry of Science and Innovation Contratos Predoctorales de Formación en Investigación en Salud (PFIS; FI20/00274); I.G.-L. was supported by a grant from the University Teacher Training Program (FPU), Ministry of Universities (FPU20/04812); and S.M.-M. was supported by the Generalitat de Catalunya “Contractació de Personal Investigador Novell (FI-DGR)” 2016 fellowship (2016FI_B 00592). This project was funded by grants from the Spanish Ministry of Science and Innovation (Fondo de Inversión en Salud [FIS] PI19/01277, which also supported I.G.-L. and S.M.-M, and Retos-Colaboración 2019 RTC2019-007067-1), La Marató TV3, the Generalitat de Catalunya AGAUR 2017 grant SGR-3193, and the European Research Council (ERC-PoC II/3079/SYST-iMYC [813132]). We thank the rest of the Soucek laboratory for critical reading of the manuscript, and the personnel at Vall d'Hebron Research Institute (VHIR) High Technology Unit. We acknowledge Vall d'Hebron Institute of Oncology and the Cellex Foundation for providing research facilities and equipment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The long journey to bring a Myc inhibitor to the clinic

  • Whitfield, Jonathan R.|||0000-0002-4925-7283
  • Soucek, Laura|||0000-0002-4750-7971
Whitfield and Soucek discuss decades of research and a vast array of strategies that are finally yielding clinical trials for Myc inhibitors in cancer. The oncogene Myc is deregulated in the majority of human tumors and drives numerous hallmarks of cancer. Despite its indisputable role in cancer development and maintenance, Myc is still undrugged. Developing a clinical inhibitor for Myc has been particularly challenging owing to its intrinsically disordered nature and lack of a binding pocket, coupled with concerns regarding potentially deleterious side effects in normal proliferating tissues. However, major breakthroughs in the development of Myc inhibitors have arisen in the last couple of years. Notably, the direct Myc inhibitor that we developed has just entered clinical trials. Celebrating this milestone, with this Perspective, we pay homage to the different strategies developed so far against Myc and all of the researchers focused on developing treatments for a target long deemed undruggable.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding

  • Massó Vallés, Daniel|||0000-0003-4231-0456
  • Beaulieu, Marie-Eve|||0000-0001-5224-8436
  • Jauset González, Toni|||0000-0003-2869-5804
  • Giuntini, Fabio
  • Zacarías-Fluck, Mariano F.|||0000-0002-7171-4268
  • Foradada Felip, Laia|||0000-0002-0589-4360
  • Martínez-Martín, Sandra|||0000-0003-4443-0697
  • Serrano, Erika
  • Martín-Fernández, Génesis|||0000-0002-1052-9763
  • Casacuberta-Serra, Sílvia|||0000-0002-2595-1115
  • Castillo Cano, Virginia
  • Kaur, Jastrinjan|||0000-0002-4474-5093
  • López-Estévez, Sergio|||0000-0001-5355-8073
  • Morcillo, Miguel Ángel|||0000-0002-1984-5834
  • Alzrigat, Mohammad|||0000-0001-5514-8625
  • Mahmoud, Loay
  • Luque-García, Antonio|||0000-0001-5785-8436
  • Escorihuela, Marta|||0000-0001-9074-2339
  • Guzmán, Marta|||0000-0002-0924-9887
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Serra, Violeta|||0000-0001-6620-1065
  • Larsson, Lars-Gunnar|||0000-0001-6914-3147
  • Whitfield, Jonathan R.|||0000-0002-4925-7283
  • Soucek, Laura|||0000-0002-4750-7971
While MYC role in metastasis has been long controversial, this manuscript demonstrates that MYC inhibition by either transgenic expression or pharmacologic use of the recombinantly produced Omomyc miniprotein exerts antitumor and antimetastatic activity in breast cancer models in vitro and in vivo, suggesting its clinical applicability.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pharmacokinetic analysis of omomyc shows lasting structural integrity and long terminal half-Life in tumor tissue

  • Beaulieu, Marie-Eve|||0000-0001-5224-8436
  • Martínez-Martín, Sandra|||0000-0003-4443-0697
  • Kaur, Jastrinjan|||0000-0002-4474-5093
  • Castillo Cano, Virginia
  • Massó Vallés, Daniel|||0000-0003-4231-0456
  • Foradada Felip, Laia|||0000-0002-0589-4360
  • López-Estévez, Sergio|||0000-0001-5355-8073
  • Serrano del Pozo, Erika|||0000-0003-2417-1499
  • Thabussot, Hugo
  • Soucek, Laura|||0000-0002-4750-7971
MYC is an oncoprotein causally involved in the majority of human cancers and a most wanted target for cancer treatment. Omomyc is the best-characterized MYC dominant negative to date. In the last years, it has been developed into a therapeutic miniprotein for solid tumor treatment and recently reached clinical stage. However, since the in vivo stability of therapeutic proteins, especially within the tumor vicinity, can be affected by proteolytic degradation, the perception of Omomyc as a valid therapeutic agent has been often questioned. In this study, we used a mass spectrometry approach to evaluate the stability of Omomyc in tumor biopsies from murine xenografts following its intravenous administration. Our data strongly support that the integrity of the functional domains of Omomyc (DNA binding and dimerization region) remains preserved in the tumor tissue for at least 72 hours following administration and that the protein shows superior pharmacokinetics in the tumor compartment compared with blood serum.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer

  • Giuntini, Fabio
  • Zacarias Fluck, Mariano F
  • Arnal, Magdalena
  • Pedretti, Flaminia
  • Grueso, Judit
  • Guzman Torres, Marta
  • González-Larreategui, Íñigo
  • Herencia Ropero, Andrea
  • Casacuberta-Serra, Sílvia
  • Serrano del Pozo, Erika
  • Rodríguez, Olga
  • Llop-Guevara, Alba
  • Balmaña, Judith
  • Nonell, Lara
  • Whitfield, Jonathan
  • Soucek, Laura
  • Serra, Violeta
Cancer; DNA damage; Omomyc, Càncer; Dany a l'ADN; Omomyc, Cáncer; Daño en el ADN; Omomyc, MYC is dysregulated in most human cancers and is a DNA damage response (DDR) modulator capable of both promoting genomic instability and enhancing DNA repair. Here, we show that Omomyc, the only direct MYC inhibitor that has completed a phase 1 trial, shuts down DDR genes in triple-negative breast cancer (TNBC), causing DDR defects and inducing DNA damage. Since DDR-deficient tumors are currently targeted by poly ADP-ribose polymerase inhibitors (PARPis), we tested combinations with Omomyc. We show that Omomyc-induced DNA damage is enhanced by PARPis and that the inhibitors cooperate even in models with intrinsic or acquired PARPi resistance, both in vitro and in vivo. Moreover, using patient-derived models and clinical samples, we reveal a role for MYC as a predictor of PARPi resistance. Overall, our research highlights the opportunity of combining MYC inhibition by Omomyc with PARPis in PARPi-resistant TNBC, where MYC transcriptional activity represents a predictive biomarker of resistance to therapy., We acknowledge the kind support from the Vall d’Hebron Institute of Oncology and the Cellex Foundation for providing research facilities and equipment. We thank the Spanish Association of Metastatic Breast Cancer for the Chiara Giorgetti Award 2022, Instituto de Salud Carlos III (FI20/00274 – F.G., PFIS doctoral bursary); Ministerio de Ciencia e Innovación (Retos de Colaboración RTC2019-007067-1 and Líneas Estratégicas PLEC2021-007959); Generalitat de Catalunya (AGAUR 2017/SGR 537 and 2021/SGR 01509); EDIReX (H2020 INFRAIA 731105-2); the European Research Council (ERC-2023-ADG 101142260); the Spanish Ministry of Science and Innovation and the European Union through the NextGenerationEU program, in the context of the Plan de Recuperacion, Transformacion y Resiliencia (RETOS; CPP2022-009808); and the Fero Foundation for funding support.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition

  • Giuntini, Fabio
  • Massó-Vallés, Daniel
  • Whitfield, Jonathan
  • Soucek, Laura
DNA damage response; DNA damage response inhibitors; MYC inhibition, Respuesta al daño del ADN; Inhibidores de la respuesta al daño del ADN; Inhibición de MYC, Resposta al dany de l'ADN; Inhibidors de la resposta al dany de l'ADN; Inhibició de MYC, MYC performs a dual role in DNA Damage Response (DDR), promoting genomic instability through replication stress, R-loop formation, and topoisomerase-mediated damage, while simultaneously activating DNA repair pathways to maintain cell survival. This review provides a comprehensive analysis of how MYC inhibition affects DDR pathway dependencies. In fact, when MYC is inhibited, cancer cells lose both their proficient DNA repair capacity and their protective mechanisms against replication stress. This creates a therapeutic window in which combining MYC inhibitors with DDR-targeting agents may achieve synergistic anti-cancer effects. Central to this approach is the exploration of rational combination strategies that pair MYC inhibitors with various DDR modulators including Poly (ADP-ribose) polymerase (PARP) inhibitors, ATR/CHK1 inhibitors, and other DNA repair pathway disruptors. This review summarizes preclinical evidence demonstrating enhanced therapeutic efficacy when MYC inhibition is combined with DDR-targeting agents and discusses early clinical findings that support this promising therapeutic strategy., The author(s) declared that financial support was received for this work and/or its publication. We thank the Spanish Association of Metastatic Breast Cancer for the Chiara Giorgetti Award 2022, Instituto de Salud Carlos III (FI20/00274 – FG PFIS doctoral bursary), Ministerio de Ciencia e Innovación (Retos de Colaboración RTC2019-007067-1, Líneas Estratégicas PLEC2021-007959), Generalitat de Catalunya (AGAUR 2017/SGR 537 and 2021/SGR 01509), EDIReX (H2020 INFRAIA 731105-2), the European Research Council (ERC-2023-ADG 101142260), the Spanish Ministry of Science and Innovation and European Union through the NextGenerationEU program, in the context of the Plan de Recuperacion, Transformacion y Resiliencia (RETOS; CPP2022-009808) and the FERO foundation for funding support.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma

  • Zacarias Fluck, Mariano F
  • Massó-Vallés, Daniel
  • Giuntini, Fabio
  • González-Larreategui, Íñigo
  • Kaur, Jastrinjan
  • Casacuberta-Serra, Sílvia
  • Jauset González, Antoni
  • Martínez Martín, Sandra
  • Martín Fernández, Génesis
  • Serrano del Pozo, Erika
  • Foradada Felip, Laia
  • Grueso Gragera, Judit
  • Nonell Malezon, Lara
  • Whitfield, Jonathan
  • Beaulieu, Marie-Eve
  • Soucek, Laura
MYC; Omomyc; Melanoma, MYC; Omomyc; Melanoma, MYC; Omomyc; Melanoma, MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway—the most predominantly mutated pathway in this disease—turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. Here, by making use of Omomyc, the most characterized MYC inhibitor to date that has just successfully completed a phase I clinical trial, we show for the first time that MYC inhibition in melanoma induces remarkable transcriptional modulation, resulting in severely compromised tumor growth and a clear abrogation of metastatic capacity independently of the driver mutation. By reducing MYC's transcriptional footprint in melanoma, Omomyc elicits gene expression profiles remarkably similar to those of patients with good prognosis, underlining the therapeutic potential that such an approach could eventually have in the clinic in this dismal disease., M.F.Z.-F. was supported by the Juan de la Cierva Programme of the Spanish Ministry of Economy and Competitiveness (IJCI-2014-22403) and Fundació La Marató de TV3 (grant 474/C/2019); F.G. was supported by Spanish Ministry of Science and Innovation Contratos Predoctorales de Formación en Investigación en Salud (PFIS; FI20/00274); I.G.-L. was supported by a grant from the University Teacher Training Program (FPU), Ministry of Universities (FPU20/04812); and S.M.-M. was supported by the Generalitat de Catalunya “Contractació de Personal Investigador Novell (FI-DGR)” 2016 fellowship (2016FI_B 00592). This project was funded by grants from the Spanish Ministry of Science and Innovation (Fondo de Inversión en Salud [FIS] PI19/01277, which also supported I.G.-L. and S.M.-M, and Retos-Colaboración 2019 RTC2019-007067-1), La Marató TV3, the Generalitat de Catalunya AGAUR 2017 grant SGR-3193, and the European Research Council (ERC-PoC II/3079/SYST-iMYC [813132]). We thank the rest of the Soucek laboratory for critical reading of the manuscript, and the personnel at Vall d'Hebron Research Institute (VHIR) High Technology Unit. We acknowledge Vall d'Hebron Institute of Oncology and the Cellex Foundation for providing research facilities and equipment.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Pharmacokinetic Analysis of Omomyc Shows Lasting Structural Integrity and Long Terminal Half-Life in Tumor Tissue

  • Martínez Martín, Sandra
  • Castillo Cano, Virginia
  • Massó Vallés, Daniel
  • López-Estévez, Sergio
  • Thabussot, Hugo
  • Beaulieu, Marie-Eve
  • Soucek, Laura
  • Foradada Felip, Laia
  • Kaur, Jastrinjan
  • Serrano del Pozo, Erika
Omomyc; Mass spectrometry; Protein therapeutics, Omomyc; Espectrometría de masas; Terapéutica de proteínas, Omomyc; Espectrometria de masses; Terapèutica de proteïnes, MYC is an oncoprotein causally involved in the majority of human cancers and a most wanted target for cancer treatment. Omomyc is the best-characterized MYC dominant negative to date. In the last years, it has been developed into a therapeutic miniprotein for solid tumor treatment and recently reached clinical stage. However, since the in vivo stability of therapeutic proteins, especially within the tumor vicinity, can be affected by proteolytic degradation, the perception of Omomyc as a valid therapeutic agent has been often questioned. In this study, we used a mass spectrometry approach to evaluate the stability of Omomyc in tumor biopsies from murine xenografts following its intravenous administration. Our data strongly support that the integrity of the functional domains of Omomyc (DNA binding and dimerization region) remains preserved in the tumor tissue for at least 72 hours following administration and that the protein shows superior pharmacokinetics in the tumor compartment compared with blood serum., This research has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 872212 and from the Ministerio de Ciencia e Innovacion under grant no. RTC2019-007067-1.